CGRP receptor antagonists: all 148 studies that test it

Page 1 of 2. Open to participants first (36), then studies with results posted, then the rest; newest registration first within each.

• A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare ProfessionalsNot yet recruitingNCT07918053Not applicable
• A Prospective Interventional Study of Intranasal Zavegepant for the Acute Treatment of MigraineNot yet recruitingNCT07861412Not applicable
• Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard TherapyRecruitingNCT07835035Phase 1
• Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With MigraineNot yet recruitingNCT07826910Phase 4
• Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell CarcinomaNot yet recruitingNCT07812467Phase 2
• Rimegepant For Endometriosis PainNot yet recruitingNCT07795125Phase 2
• A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority StudyNot yet recruitingNCT07751497Phase 2
• A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic MigraineRecruitingNCT07729462Phase 3
• Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster HeadacheNot yet recruitingNCT07714369Phase 2
• A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in IndiaRecruitingNCT07685769Phase 4
• A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency DepartmentRecruitingNCT07667621Phase 1
• Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)Not yet recruitingNCT07655440Phase 4
• Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCLNot yet recruitingNCT07613788Phase 2
• A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With MigraineRecruitingNCT07609914Phase 4
• Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingNCT07475234Phase 1/2
• Efficacy and Safety of Rimegepant for Acute DizzinessNot yet recruitingNCT07435090Phase 2/3
• Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the USRecruitingNCT07301008Phase 4
• Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer PatientsNot yet recruitingNCT06999252Phase 2
• A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of MigraineRecruitingNCT06995729Phase 1
• Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyRecruitingNCT06972056Phase 4
• A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 YearsRecruitingNCT06810505Phase 3
• A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experimentNot yet recruitingNCT06748664Phase 2
• A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigraineRecruitingNCT06641466Phase 3
• A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine HeadacheRecruitingNCT06473597Phase 4
• Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive MedicationsRecruitingNCT06401642Phase 4
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigraineRecruitingNCT05711394Phase 3
• Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With MigraineEnrolling by invitationNCT05707949Phase 3
• Screening Trial for Pain Relief in Schwannomatosis (STARFISH)RecruitingNCT05684692Phase 2
• Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric SubjectsRecruitingNCT05156398Phase 3
• Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)Enrolling by invitationNCT05127954Phase 3
• Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)RecruitingNCT05125302Phase 3
• Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBIRecruitingNCT05049057Phase 2
• Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of MigraineRecruitingNCT04743141Phase 3
• Registry for Migraine - Structural and Functional MRI Before and After Erenumab TreatmentRecruitingNCT04674020Phase 4
• Randomized Study in Children and Adolescents With Migraine: Acute TreatmentRecruitingNCT04649242Phase 3
• Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With ErenumabRecruitingNCT04592952Phase 4
• Comparison of Rimegepant and Placebo for Pain in IBSCompletedNCT06221111Phase 2Results posted
• A Study to Learn About the Study Medication, Zavegepant, in Healthy VolunteersCompletedNCT06137703Phase 1Results posted
• A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian AdultsCompletedNCT05989048Phase 3Results posted
• A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult ParticipantsCompletedNCT05960032Phase 1Results posted
• A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric MicrosamplingCompletedNCT05948085Phase 1Results posted
• Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic MigraineCompletedNCT05861427Phase 3Results posted
• A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.CompletedNCT05810038Phase 3Results posted
• Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive MedicationsCompletedNCT05518123Phase 4Results posted
• Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan UseCompletedNCT05509400Phase 4Results posted
• Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)CompletedNCT05399485Phase 3Results posted
• Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)CompletedNCT05399459Phase 3Results posted
• A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese ParticipantsCompletedNCT05371652Phase 3Results posted
• Real World Effectiveness of Eptinezumab in Participants With MigraineTerminatedNCT05284019Phase 4Results posted
• Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With MigraineCompletedNCT05264129Phase 4Results posted
• Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular DisordersTerminatedNCT05262517Phase 3Results posted
• Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic RhinosinusitisCompletedNCT05248997Phase 3Results posted
• Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing RegimensCompletedNCT05217927Phase 4Results posted
• Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic MigraineCompletedNCT05216263Phase 3Results posted
• Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine PreventionCompletedNCT05207865Phase 4Results posted
• Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)TerminatedNCT05162027Phase 2Results posted
• Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.TerminatedNCT05142228Phase 2Results posted
• Safety and Efficacy Active Drug vs. Placebo in Subjects With AsthmaTerminatedNCT04987944Phase 1Results posted
• Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular DisorderCompletedNCT04884763Phase 2Results posted
• An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute HeadacheCompletedNCT04860713Phase 4Results posted
• Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic MigraineCompletedNCT04829747Phase 3Results posted
• A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With MigraineCompletedNCT04825678Phase 4Results posted
• A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine PreventionTerminatedNCT04804033Phase 2/3Results posted
• Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.CompletedNCT04740827Phase 3Results posted
• Rimegepant in Moderate Plaque-type PsoriasisCompletedNCT04629950Phase 2Results posted
• Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of MigraineCompletedNCT04574362Phase 3Results posted
• Randomized Trial in Adult Participants With Acute MigrainesCompletedNCT04571060Phase 3Results posted
• Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult ParticipantsCompletedNCT04492020Phase 3Results posted
• Efficacy of Erenumab on Functional Impact of MigraineCompletedNCT04465357Phase 4Results posted
• A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic MigraineCompletedNCT04437433Phase 3Results posted
• Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of MigraineCompletedNCT04408794Phase 2/3Results posted
• Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental OxygenTerminatedNCT04346615Phase 2/3Results posted
• Erenumab For Treatment of Hemicrania ContinuaTerminatedNCT04303845Phase 2Results posted
• Biomarker and Genetic Predictors of Erenumab Treatment ResponseCompletedNCT04265755Phase 4Results posted
• Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic MigraineCompletedNCT04252742Phase 4Results posted
• Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With MigraineCompletedNCT04179474Phase 1Results posted
• Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTHCompletedNCT04098250Phase 2Results posted
• Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label StudyCompletedNCT04084314Phase 4Results posted
• A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse HeadacheCompletedNCT03971071Phase 4Results posted
• Trial for Treatment Refractory Trigeminal NeuralgiaTerminatedNCT03941834Phase 2Results posted
• Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic MigraineCompletedNCT03939312Phase 3Results posted
• Study of Sustained Benefit of AMG334 in Adult Episodic Migraine PatientsCompletedNCT03927144Phase 4Results posted
• Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic MigraineTerminatedNCT03912337Phase 4Results posted
• Acute Treatment Trial in Adult Subjects With MigrainesCompletedNCT03872453Phase 2/3Results posted
• Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine PatientsCompletedNCT03867201Phase 3Results posted
• Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic MigraineCompletedNCT03855137Phase 3Results posted
• Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic MigraineCompletedNCT03832998Phase 3Results posted
• Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic MigraineCompletedNCT03828539Phase 4Results posted
• A Controlled Trial of Erenumab in Migraine PreventionCompletedNCT03812224Phase 3Results posted
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic MigraineCompletedNCT03777059Phase 3Results posted
• Imaging the Migraine Brain Pre- and Post-ErenumabCompletedNCT03773562Phase 4Results posted
• Efficacy and Safety Trial of Rimegepant for Migraine Prevention in AdultsCompletedNCT03732638Phase 2/3Results posted
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic MigraineCompletedNCT03700320Phase 3Results posted
• AMG 334 20160172 Pediatric Migraine PK Study.CompletedNCT03499119Phase 1Results posted
• Trial in Adult Subjects With Acute MigrainesCompletedNCT03461757Phase 3Results posted
• Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine PatientsCompletedNCT03333109Phase 3Results posted
• Open Label Safety Study in Acute Treatment of MigraineCompletedNCT03266588Phase 2/3Results posted
• Safety and Efficacy in Adult Subjects With Acute MigrainesCompletedNCT03237845Phase 3Results posted
• Safety and Efficacy Study in Adult Subjects With Acute MigrainesCompletedNCT03235479Phase 3Results posted
• A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other TherapiesCompletedNCT03096834Phase 3Results posted

← CGRP receptor antagonists overview